{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:12Z","timestamp":1784822592590,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00942-y","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:21:14Z","timestamp":1777656074000},"page":"1663-1674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding the Unmet Needs of People with MS at Diagnosis and Throughout Their Care Journey: Insights from a Survey-Based Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-8893","authenticated-orcid":false,"given":"Klaus","family":"Schmierer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"van Galen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5599-9788","authenticated-orcid":false,"given":"Alice","family":"Laroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Montague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanca","family":"Potra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0770-3628","authenticated-orcid":false,"given":"Heidi","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"3","key":"942_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3988\/jcn.2022.0208","volume":"19","author":"AB Baskaran","year":"2023","unstructured":"Baskaran AB, Grebenciucova E, Shoemaker T, Graham EL. Current updates on the diagnosis and management of multiple sclerosis for the general neurologist. J Clin Neurol. 2023;19(3):217\u201329.","journal-title":"J Clin Neurol"},{"key":"942_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2025.100553","volume":"38","author":"B Yamout","year":"2025","unstructured":"Yamout B. Update in Multiple Sclerosis. eNeurologicalSci. 2025;38:100553.","journal-title":"eNeurologicalSci"},{"issue":"Pt 3","key":"942_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/brain\/120.3.393","volume":"120","author":"B Ferguson","year":"1997","unstructured":"Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120(Pt 3):393\u20139.","journal-title":"Brain"},{"issue":"3","key":"942_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/ana.25835","volume":"88","author":"N Petrova","year":"2020","unstructured":"Petrova N, Nutma E, Carassiti D, et al. Synaptic loss in multiple sclerosis spinal cord. Ann Neurol. 2020;88(3):619\u201325.","journal-title":"Ann Neurol"},{"issue":"14","key":"942_CR5","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler. 2020;26(14):1816\u201321.","journal-title":"Mult Scler"},{"issue":"11","key":"942_CR6","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s40265-025-02212-x","volume":"85","author":"L Zuroff","year":"2025","unstructured":"Zuroff L, Farkhondeh V, Bove R, Green AJ. The road to remyelination in multiple sclerosis: breakthroughs, challenges, and considerations for future trial design. Drugs. 2025;85(11):1337\u201362.","journal-title":"Drugs"},{"issue":"1","key":"942_CR7","first-page":"1","volume":"19","author":"N Ghasemi","year":"2017","unstructured":"Ghasemi N, Razavi S, Nikzad E. Multiple Sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19(1):1\u201310.","journal-title":"Cell J"},{"issue":"1","key":"942_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40120-021-00239-2","volume":"10","author":"L Lakin","year":"2021","unstructured":"Lakin L, Davis BE, Binns CC, Currie KM, Rensel MR. Comprehensive approach to management of multiple sclerosis: addressing invisible symptoms\u2014a narrative review. Neurol Ther. 2021;10(1):75\u201398.","journal-title":"Neurol Ther"},{"key":"942_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1015256","volume":"13","author":"S Simoens","year":"2022","unstructured":"Simoens S. Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies. Front Neurol. 2022;13:1015256.","journal-title":"Front Neurol"},{"issue":"2","key":"942_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10198-022-01471-9","volume":"24","author":"B Rodr\u00edguez-S\u00e1nchez","year":"2023","unstructured":"Rodr\u00edguez-S\u00e1nchez B, Daugbjerg S, Pe\u00f1a-Longobardo LM, et al. Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease. Eur J Health Econ. 2023;24(2):247\u201377.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"942_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/ajhp\/zxad247","volume":"81","author":"A Edinger","year":"2023","unstructured":"Edinger A, Habibi M. The evolution of multiple sclerosis disease-modifying therapies: an update for pharmacists. Am J Health Syst Pharm. 2023;81(2):37\u201355.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"942_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ncl.2020.09.002","volume":"39","author":"C Goldschmidt","year":"2021","unstructured":"Goldschmidt C, McGinley MP. Advances in the treatment of multiple sclerosis. Neurol Clin. 2021;39(1):21\u201333.","journal-title":"Neurol Clin"},{"key":"942_CR13","doi-asserted-by":"publisher","first-page":"799138","DOI":"10.3389\/fneur.2021.799138","volume":"12","author":"BL Vollmer","year":"2022","unstructured":"Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E. Evolution of disease modifying therapy benefits and risks: an argument for de-escalation as a treatment paradigm for patients with multiple sclerosis. Front Neurol. 2022;12:799138.","journal-title":"Front Neurol"},{"key":"942_CR14","doi-asserted-by":"publisher","first-page":"105092","DOI":"10.1016\/j.msard.2023.105092","volume":"80","author":"NF Col","year":"2023","unstructured":"Col NF, Solomon AJ, Alvarez E, et al. Implementing shared decision-making for multiple sclerosis: the MS-SUPPORT tool. Multiple Scler Relat Disord. 2023;80:105092.","journal-title":"Multiple Scler Relat Disord"},{"key":"942_CR15","doi-asserted-by":"publisher","first-page":"1063904","DOI":"10.3389\/fneur.2022.1063904","volume":"13","author":"DT Ubbink","year":"2022","unstructured":"Ubbink DT, Damman OC, de Jong BA. Shared decision-making in patients with multiple sclerosis. Front Neurol. 2022;13:1063904.","journal-title":"Front Neurol"},{"issue":"8","key":"942_CR16","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s10072-020-04339-z","volume":"41","author":"C Tortorella","year":"2020","unstructured":"Tortorella C, Solaro C, Annovazzi P, et al. Informing MS patients on treatment options: a consensus on the process of consent taking. Neurol Sci. 2020;41(8):2249\u201353.","journal-title":"Neurol Sci"},{"issue":"5","key":"942_CR17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/09638288.2022.2046187","volume":"45","author":"G Topcu","year":"2023","unstructured":"Topcu G, Mhizha-Murira JR, Griffiths H, et al. Experiences of receiving a diagnosis of multiple sclerosis: a meta-synthesis of qualitative studies. Disabil Rehabil. 2023;45(5):772\u201383.","journal-title":"Disabil Rehabil"},{"key":"942_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106342","volume":"95","author":"M Savio","year":"2025","unstructured":"Savio M, Kearney H, Giunti G. Evaluating the evidence behind multidisciplinary roles for a multiple sclerosis unit: a systematic literature review. Mult Scler Relat Disord. 2025;95:106342.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"942_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"University of California SFMSET, Cree BAC, Hollenbach JA, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653\u201366.","journal-title":"Ann Neurol"},{"issue":"9","key":"942_CR20","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132\u201340.","journal-title":"JAMA Neurol"},{"key":"942_CR21","unstructured":"PIF TICK. https:\/\/piftick.org.uk\/. Accessed Dec 2025."},{"issue":"1","key":"942_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12883-025-04148-x","volume":"25","author":"F Bayat","year":"2025","unstructured":"Bayat F, Negarandeh R, Pashaeypoor S. The effect of patient-centered empowerment program through telenursing on self-management in people with multiple sclerosis: a double-blinded randomized clinical trial. BMC Neurol. 2025;25(1):138.","journal-title":"BMC Neurol"},{"issue":"4","key":"942_CR23","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/scs.12601","volume":"32","author":"D Appleton","year":"2018","unstructured":"Appleton D, Robertson N, Mitchell L, Lesley R. Our disease: a qualitative meta-synthesis of the experiences of spousal\/partner caregivers of people with multiple sclerosis. Scand J Caring Sci. 2018;32(4):1262\u201378.","journal-title":"Scand J Caring Sci"},{"issue":"1","key":"942_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40120-021-00299-4","volume":"11","author":"J Kesselring","year":"2022","unstructured":"Kesselring J, Boyko A, Laroni A, Bharadia T, van Galen P, Alexandri N. Caregiver involvement in MS: duty or disruption? Neurol Ther. 2022;11(1):9\u201320.","journal-title":"Neurol Ther"},{"issue":"23","key":"942_CR25","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1080\/09638288.2020.1741698","volume":"43","author":"LS Parker","year":"2021","unstructured":"Parker LS, Topcu G, De Boos D, das Nair R. The notion of \u201cinvisibility\u201d in people\u2019s experiences of the symptoms of multiple sclerosis: a systematic meta-synthesis. Disabil Rehabil. 2021;43(23):3276\u201390.","journal-title":"Disabil Rehabil"},{"key":"942_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/PPA.S268829","volume":"15","author":"EG Celius","year":"2021","unstructured":"Celius EG, Thompson H, Pontaga M, et al. Disease progression in multiple sclerosis: a literature review exploring patient perspectives. Patient Prefer Adherence. 2021;15:15\u201327.","journal-title":"Patient Prefer Adherence"},{"key":"942_CR27","first-page":"496","volume":"328","author":"S Guardado","year":"2025","unstructured":"Guardado S, Tripathi N, Isomursu M, Giunti G. Adoption of mHealth apps in chronic care: healthcare professionals\u2019 views. Stud Health Technol Inform. 2025;328:496\u2013500.","journal-title":"Stud Health Technol Inform"},{"issue":"9","key":"942_CR28","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00415-025-13320-9","volume":"272","author":"M Jaworski 3rd","year":"2025","unstructured":"Jaworski M 3rd, Balconi J, Santivasci C, et al. Improving conscientiousness through a smartphone app and telecoaching intervention: insights from multiple sclerosis and healthy aging samples. J Neurol. 2025;272(9):580.","journal-title":"J Neurol"},{"issue":"8","key":"942_CR29","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1080\/09638288.2025.2549528","volume":"48","author":"E Fragkiadaki","year":"2026","unstructured":"Fragkiadaki E, Nizza IE, Starr R, Smith JA, Rice C, Cotterill N. Trajectories of change in experiences of multiple sclerosis: insights from an online group psychological intervention. Disabil Rehabil. 2026;48(8):2362\u201378.","journal-title":"Disabil Rehabil"},{"issue":"13","key":"942_CR30","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1177\/1352458518809326","volume":"25","author":"J Hobart","year":"2019","unstructured":"Hobart J, Bowen A, Pepper G, et al. International consensus on quality standards for brain health-focused care in multiple sclerosis. Mult Scler. 2019;25(13):1809\u201318.","journal-title":"Mult Scler"},{"issue":"2","key":"942_CR31","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/hex.13711","volume":"26","author":"T Tindall","year":"2023","unstructured":"Tindall T, Topcu G, Thomas S, et al. Developing a patient care pathway for emotional support around the point of multiple sclerosis diagnosis: a stakeholder engagement study. Health Expect. 2023;26(2):858\u201368.","journal-title":"Health Expect"},{"issue":"Suppl 2","key":"942_CR32","first-page":"A76","volume":"95","author":"K Schmierer","year":"2024","unstructured":"Schmierer K, Mathews J, Stennett A, et al. Coaching newly diagnosed people with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2024;95(Suppl 2):A76\u2013A76.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00942-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:31Z","timestamp":1784819491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00942-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["942"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00942-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Klaus Schmierer has received speaker honoraria from Neuraxpharm, Novartis, Roche, Sanofi, the healthcare business of Merck KGaA, Darmstadt, Germany and EMD Serono Research & Development Institute, Inc., Billerica, MA, an affiliate of Merck KGaA, Darmstadt, Germany; research grants, through\u00a0Queen Mary University of London,\u00a0from Biogen, JUVISE, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche and Sandoz; he is Chair of the MACiMiSE-BRAIN DMEC and has received service support, through Queen Mary University of London and Barts Health NHS Trust, from\u00a0Neuraxpharm. Pieter van Galen has received consulting fees from Roche and the healthcare business of Merck KGaA, Darmstadt, Germany. Helen Gray is an employee of Merck Serono (Ireland) Ltd., Dublin, Ireland, an affiliate of Merck KGaA, Darmstadt, Germany. Alice Laroni received grants or contracts from the Italian Ministry of Health, the Italian Ministry of University and IRCSS Ospedale San Martino; consulting fees from Novartis, the healthcare business of Merck KGaA, Darmstadt, Germany, Biogen and Roche; speaker honoraria from Novartis, Sanofi, the healthcare business of Merck KGaA, Darmstadt, Germany, Biogen, BMS and Roche; and support for attending meetings from Roche, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis and Biogen. Amanda Montague\u2019s institution (Multiple Sclerosis Association of America) received grants and contracts from Genentech, EMD Serono, Boston, MA, Novartis, TG Therapeutics, Sanofi, BMS and Biogen. Stanca Potra received support for meeting attendance from Roche, and the healthcare business of Merck KGaA, Darmstadt, Germany. Heidi Thompson received speaker honoraria from Novartis, Roche and the healthcare business of Merck KGaA, Darmstadt, Germany.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All participants provided informed consent and data were anonymised. The survey protocols were reviewed by an independent institutional review board, WCG Clinical (Cary, NC, USA), and determined to be exempt from full review (Protocol numbers 5653 and 5652 for the \u2018Patient Empowerment\u2019 and \u2018Needs at Diagnosis\u2019 surveys, respectively).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}